Related Experiment Video
Updated: May 19, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Outcome of venom bradykinin potentiating factor on rennin-angiotensin system in irradiated rats
Omaima Ashry1, Mohamed Moustafa, Ahmed Abd El Baset
1Radiation Biology Department, National Centre for Radiation Research and Technology (NCRRT), Cairo, Egypt. Omaimashry@yahoo.com
Purpose:
The objective of this work was to compare the effect of a bradykinin potentiating (BPF) isolated from venom of Egyptian scorpion Androctonus amoreuxi as a natural angiotensin converting enzyme inhibitor (ACEI) with losartan (LOS), a chemical angiotensin receptor blocker (ARB), in the modulation of radiation-induced damage.
Material And Methods:
Rats were grouped into: (i)
Control:
untreated; (ii) + C(BPF): Received intraperitoneally (i.p.) BPF 1 μg/g body weight (b.w.) (twice/week) during 3 weeks; (iii) + C(LOS:) Received i.p. LOS 5 μg/g b.w. (twice/week) during 3 weeks; (iv) R: Irradiated at 4 Gy; (v) R + BPF and (vi) R + LOS: Received BPF or LOS post-irradiation for 3 weeks.
Results:
BPF or LOS treatment induced a significant drop of sodium and uric acid. Irradiation induced a significant elevation of malondialdehyde (MDA) and advanced oxidation protein product (AOPP) associated with a significant decrease of glutathione (GSH) content in the kidney. Serum aldosterone, sodium, urea and creatinine levels showed a significant increase while a significant drop was recorded for haematological values, calcium and uric acid levels. Treatment of irradiated animals with BPF or LOS significantly improved radiation-induced changes.
Conclusion:
It could be concluded that the use of BPF as a natural product is comparable to the chemical compound LOS.
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Hypertension II: Pathophysiology
Hormonal Regulation
